Current status for high titre poxvirus stock preparation in CEF under serum-free medium conditions: Implication for vaccine development

Philippe Alexandre Gilbert, Lacrimioara Comanita, John Barrett, Andrew Peters, Marta Szabat, Grant McFadden, Gregory A. Dekaban

Research output: Contribution to journalArticle

9 Scopus citations

Abstract

In light of the recent detection of BSE in North America and its endemic nature in other regions of the world, there is a real need to employ cell culture conditions that do not require any animal-derived material. Here we report the use of an ultra-low protein serum-free medium (VP-SFM, Invitrogen) for the amplification of poxviruses in primary chicken embryo fibroblasts (CEF). We compared the amplification of four different poxviruses (canarypox, modified Ankara Virus (MVA), vaccinia virus strain Copenhagen and myxoma strain Lausanne) in three different media: DMEM 10%, DMEM 2% and serum-free medium VP-SFM. VP-SFM is a serum-free, ultra-low protein medium containing no proteins or peptides of human or animal origin designed to support the replication of viruses and the production of recombinant proteins and monoclonal antibodies. Our results show that high titre poxvirus stocks can be prepared in VP-SFM equivalent to that prepared in serum containing medium.

Original languageEnglish (US)
Pages (from-to)79-88
Number of pages10
JournalCytotechnology
Volume48
Issue number1-3
DOIs
StatePublished - Jan 2005

Keywords

  • Canarypox virus (ALVAC)
  • Chicken embryo fibroblasts (CEF)
  • Modified Ankara Virus (MVA)
  • Poxvirus
  • Serum-free medium
  • VP-SFM
  • Vaccinia virus

ASJC Scopus subject areas

  • Biotechnology
  • Bioengineering
  • Biomedical Engineering
  • Clinical Biochemistry
  • Cell Biology

Fingerprint Dive into the research topics of 'Current status for high titre poxvirus stock preparation in CEF under serum-free medium conditions: Implication for vaccine development'. Together they form a unique fingerprint.

  • Cite this